Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0ELIAQ
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Anti-CD33AB-Compound (Ie)
|
|||||
| Synonyms |
Anti CD33AB Compound (Ie)
Click to Show/Hide
|
|||||
| Organization |
Orum Therapeutics, Inc.
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 1 Indication(s)
Acute myeloid leukaemia [ICD11:2A60]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
3.25
|
|||||
| Structure |
|
|||||
| Antibody Name |
Anti-CD33AB
|
Antibody Info | ||||
| Antigen Name |
Myeloid cell surface antigen CD33 (CD33)
|
Antigen Info | ||||
| Payload Name |
NeoDegrader P1
|
Payload Info | ||||
| Therapeutic Target |
Protein cereblon (CRBN)
|
Target Info | ||||
| Linker Name |
Anti-CD33AB-Compound (Ie) linker
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 80.84% (Day 46) | Positive CD33 expression (CD33+++/++) | ||
| Method Description |
1 x 107 MV411 human acute monocytic leukemia cells in 50% Matrigel were injected subcutaneously in the flank of the mice (0.1 mL/mouse). The mice were dosed with anti-CD33 antibody-neoDegrader conjugates and vehicle control once tumors reached an average size of 100-150 mm3. The stock solutions of CD33AB-Compound (le) was diluted with vehicle, which provided, 2.83 mg/kg in a dosing volume of 10 mL/kg (0.2 mL per 20 g mouse).
Click to Show/Hide
|
||||
| In Vivo Model | MV411 CDX model | ||||
| In Vitro Model | Childhood acute monocytic leukemia | MV4-11 cells | CVCL_0064 | ||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.